News | May 17, 2007

FDA Puts Medicure’s Ischemia Drug on the Fast Track

May 18, 2007 — Medicure, a biopharmaceutical company focused on the research, development and commercialization of novel compounds to treat cardiovascular disorders, is developing MC-1 for the treatment of acute ischemia and ischemic reperfusion injury, and has received a Fast Track Designation from the FDA for the drug.

Currently, MC-1 has completed two positive Phase 2 studies, one in angioplasty patients and most recently a 901-patient coronary artery bypass graft (CABG) study, called MEND-CABG.

In the MEND-CABG study, patients undergoing coronary artery bypass graft surgery who received biopharmaceutical company Medicure’s lead drug MC-1 in Phase II clinical trails showed a 47 percent decrease in postoperative hearts attacks. MC-1 is currently being evaluated in a Phase 3 trial (MEND-CABG II) that is enrolling up to 3,000 patients undergoing CABG surgery at approximately 120 cardiac surgical centers throughout North America and Europe . Medicure is conducting the Phase 3 study in conjunction with the Duke Clinical Institute (DCRI) and Montreal Heart Institute (MHI). If successful, the trial could lead to approval of MC-1 for sale in the U.S.

"Some doctors have been less inclined to recommend bypass surgery for their patients because of the risk associated with the procedure, including postoperative heart attacks,” stated Dr. Robert Harrington of Duke Clinical Research Institute. “Unfortunately there are currently no approved drugs to specifically lessen that risk."

For more information visit

Related Content

Farxiga Reduces Heart Failure Hospitalization, Cardiovascular Death for Type 2 Diabetes
News | Pharmaceuticals | November 15, 2018
AstraZeneca announced positive full results from the DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) for...
Vascepa and Statins Significantly Reduce Cardiovascular Events in the REDUCE-IT trial. #AHA #AHA18 #AHA2018
News | Pharmaceuticals | November 13, 2018
A study in the current edition of the New England Journal of Medicine shows that a particular treatment significantly...
Evolocumab Benefits High-Risk Patients With Established Cardiovascular and Chronic Kidney Disease
News | Pharmaceuticals | October 31, 2018
Amgen announced a new Repatha cardiovascular outcomes study (FOURIER) analysis evaluating the effects of Repatha (...
Jardiance Improves Life Expectancy for Adults With Type 2 Diabetes and Cardiovascular Disease
News | Pharmaceuticals | October 11, 2018
Novel results from the landmark EMPA-REG OUTCOME trial suggest that treatment with Jardiance positively impacts life...
Effect of Daily Aspirin on First-Time Heart Attack and Stroke Risk Inconclusive
News | Pharmaceuticals | September 04, 2018
The jury is still out on whether people at moderate risk of a first heart attack or stroke should take daily aspirin to...
Blood Pressure and Cholesterol-lowering Drugs Continue to Improve Survival After a Decade
News | Pharmaceuticals | August 27, 2018
Blood pressure and cholesterol-lowering drugs continue to improve survival in patients with hypertension after more...
Pfizer Announces Positive Topline Results from Phase 3 ATTR-ACT Study
News | Pharmaceuticals | April 06, 2018
Pfizer Inc. announced that the Tafamidis Phase 3 Transthyretin Cardiomyopathy (ATTR-ACT) study met its primary endpoint...
Humanetics Presents Data on Drug to Protect Cardiac Cells From Space-Like Radiation

Photo from NASA

News | Pharmaceuticals | February 01, 2018
February 1, 2018 –Humanetics Corporation (Humanetics) has recently completed two research studies funded by the Natio
Xarelto Significantly Reduces Major Cardioavascular Events in Stable CAD and PAD Patients
News | Pharmaceuticals | October 18, 2017
October 18, 2017 — Results from the pivotal Phase 3 COMPASS study found that the...
Overlay Init